Pathstone Family Office’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pathstone Family Office’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$211K	Buy	+1,628	New	+$217K	﹤0.01%	1492
2022 Q4	–	Sell	-2,043	Closed	-$272K	–	1357
2022 Q3	$272K	Buy	+2,043	New	+$311K	0.01%	966
2014 Q4	–	Sell	-50	Closed	-$8K	–	178
2014 Q3	$8K	Buy	+50	New	+$7.69K	0.02%	234

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Pathstone Family Office's JAZZ Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2023: 1,628 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #1492 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in JAZZ as recently as Q3 2022.

Pathstone Family Office first reported a position in JAZZ in Q3 2014 and has held it in 3 quarters since. The position peaked at $272K in Q3 2022. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

Pathstone Family Office held 1,628 shares of Jazz Pharmaceuticals worth $211K as of Q3 2023.
Jazz Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
Jazz Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1492 holding.
Pathstone Family Office first reported a position in Jazz Pharmaceuticals in Q3 2014 and has held it in 3 quarters since.
Pathstone Family Office's Jazz Pharmaceuticals position peaked at $272K in Q3 2022.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.